Department of Neurosurgery, the First Hospital of Jilin University, Changchun, China.
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, the United States of America.
PLoS One. 2019 May 23;14(5):e0216678. doi: 10.1371/journal.pone.0216678. eCollection 2019.
This study aimed to screen lead compounds and medication candidates from drug library (ZINC database) which has potential agonist effect targeting STING protein.
A series of computer-aided virtual screening techniques were utilized to identify potential agonists of STING. Structure-based screening using Libdock was carried out followed by ADME (absorption, distribution, metabolism, excretion) and toxicity prediction. Molecular docking was performed to demonstrate the binding affinity and mechanism between ligands and STING dimers. Molecular dynamic simulation was utilized to evaluate the stability of ligand-receptor complex. Finally, animal experiment was conducted to validate the effectiveness of selected compounds.
Three novel natural compounds 1,2,3 (ZINC000015149223, ZINC000011616633 and ZINC000001577210, respectively) from the ZINC15 database were found binding to STING with more favorable interaction energy. Also, they were predicted with less ames mutagenicity, rodent carcinogenicity, non-developmental toxic potential and tolerant with cytochrome P450 2D6 (CYP2D6). The ligand chemical structure analysis showed the three compounds were inborn axisymmetric, such chemical structures account for combining and activating process of STING protein dimers. The dynamic simulation analysis demonstrated that ZINC000015149223-, ZINC000011616633- and ZINC000001577210-STING dimer complex had more favorable potential energy compared with amidobenzimidazole (ABZI) and they can exist in natural environments stably. Animal experiments also demonstrated that these three compounds could suppress tumor growth.
This study demonstrates that ZINC000015149223, ZINC000011616633 and ZINC000001577210 are potential agonists targeting STING protein. These compounds are safe drug candidates and have a great significance in STING agonists development.
本研究旨在从药物库(ZINC 数据库)中筛选出针对 STING 蛋白具有潜在激动剂作用的先导化合物和候选药物。
利用一系列计算机辅助虚拟筛选技术来鉴定 STING 的潜在激动剂。采用 Libdock 进行基于结构的筛选,然后进行 ADME(吸收、分布、代谢、排泄)和毒性预测。进行分子对接以证明配体与 STING 二聚体之间的结合亲和力和机制。利用分子动力学模拟来评估配体-受体复合物的稳定性。最后,进行动物实验以验证所选化合物的有效性。
从 ZINC15 数据库中发现了三种新型天然化合物 1、2、3(ZINC000015149223、ZINC000011616633 和 ZINC000001577210),它们与 STING 结合具有更有利的相互作用能。此外,它们被预测具有较低的 Ames 致突变性、啮齿动物致癌性、非发育毒性潜力和对细胞色素 P450 2D6(CYP2D6)的耐受性。配体化学结构分析表明,这三种化合物均为内禀轴对称结构,这种化学结构占 STING 蛋白二聚体结合和激活过程。动态模拟分析表明,与 amidobenzimidazole(ABZI)相比,ZINC000015149223、ZINC000011616633 和 ZINC000001577210-STING 二聚体复合物具有更有利的势能,并且它们可以在自然环境中稳定存在。动物实验也表明,这三种化合物可以抑制肿瘤生长。
本研究表明,ZINC000015149223、ZINC000011616633 和 ZINC000001577210 是针对 STING 蛋白的潜在激动剂。这些化合物是安全的候选药物,在 STING 激动剂开发方面具有重要意义。